Combined oral contraceptives: Health benefits beyond contraception

Panminerva Medica

Volumn 56, Issue 3, 2014, Pages 233-244

  Caserta, D ^a   Ralli, E ^a   Matteucci, E ^a   Bordi, G ^a   Mallozzi, M ^a   Moscarini, M ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Combined; Contraceptives; Oral; Prevention and control; Therapy

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ACNE VULGARIS; ARTHRITIS, RHEUMATOID; BONE DENSITY; BREAST DISEASES; CLIMACTERIUM; COLORECTAL NEOPLASMS; CONTRACEPTION; DRUG EFFECTS; ENDOMETRIAL NEOPLASMS; ENDOMETRIOSIS; FEMALE; HIRSUTISM; HUMAN; MIGRAINE DISORDERS; MULTIPLE SCLEROSIS; MYOMA; OVARIAN CYSTS; OVARIAN NEOPLASMS; PELVIC INFLAMMATORY DISEASE; POLYCYSTIC OVARY SYNDROME; PREMENSTRUAL SYNDROME; PROCEDURES;

ACNE VULGARIS; ARTHRITIS, RHEUMATOID; BONE DENSITY; BREAST DISEASES; COLORECTAL NEOPLASMS; CONTRACEPTION; CONTRACEPTIVES, ORAL, COMBINED; ENDOMETRIAL NEOPLASMS; ENDOMETRIOSIS; FEMALE; HIRSUTISM; HUMANS; MIGRAINE DISORDERS; MULTIPLE SCLEROSIS; MYOMA; OVARIAN CYSTS; OVARIAN NEOPLASMS; PELVIC INFLAMMATORY DISEASE; PERIMENOPAUSE; POLYCYSTIC OVARY SYNDROME; PREMENSTRUAL SYNDROME;

EID: 84927172792     PISSN: 00310808     EISSN: 18271898     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Dhont M. History of oral contraception. Eur J Contracept Reprod Health Care 2010;(15 Suppl 2):S12-8.
2. Kubba A, Guillebaud J. Combined oral contraceptives: acceptability and effective use. Br Med Bull 1993;49:140-57.
3. Burkman R, Bell C, Serfaty D. The evolution of combined oral contraception: improving the risk-to-benefit ratio. Contraception 2011;84:19-34.
4. American Congress of Obstetricians and Gynecologists, ACOG Practice Bulletin. Noncontraceptive uses of hormonal contraceptives. Obstet Gynecol 2010;115:206-18.
5. Maia HJ, Casoy J. Non-contraceptive health benefits of oral contraceptives. Eur J Contracept Reprod Health Care 2008;13:17-24.
6. Davis AR, Westhoff C, O'Connell K, Gallagher N. Oral contraceptives for dysmenorrhea in adolescent girls:a randomized trial. Obstet Gynecol 2005;106:97-104.
7. Wong CL, Farquhar C, Roberts H, Proctor M. Oral contraceptive pill as treatment for primary dysmenorrhoea. Cochrane Database Syst Rev 2009;CD002120.
8. Zahradnik HP, Hanjalic-Beck A, Groth K. Nonsteroidal anti-inflammatory drugs and hormonal contraceptives for pain relief from dysmenorrheas review. Contraception 2010;81:185-96.
9. Harada T, Momoeda M, Terakawa N, Taketani Y, Hoshiai H. Evaluation of a low-dose oral contraceptive pill for primary dysmenorrhea: a placebo-controlled, double-blind, randomized trial. Fertil Steril 2011;95:1928-31.
10. Lindh I, Ellström AA, Milsom I. The effect of combined oral contraceptives and age on dysmenorrhoea: an epidemiological study. Hum Reprod 2012;27:676-82.
11. ESHRE Capri Workshop Group. Noncontraceptive health benefits of combined oral contraception. Hum Reprod Update 2005;11:513-25.
12. Farquhar C, Brown J. Oral contraceptive pill for heavy menstrual bleeding. Cochrane Database Syst Rev 2009;CD000154.
13. Kiley J, Hammond C. Combined oral contraceptives: a comprehensive review. Clin Obstet Gynecol 2007;50:868-77.
14. King J. Noncontraceptive uses of hormonal contraception. J Midwifery Womens Health 2011;56:628-35.
15. Fraser IS, Kovacs GT. The efficacy of non-contraceptive uses for hormonal contraceptives. Med J Aust 2003;178:621-3.
16. Nilsson L, Rybo G. Treatment of menorrhagia. Am J Obstet Gynecol 1971;110:713-20.
17. Davis A, Godwin A, Lippman J, Olson W, Kafrissen M. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynecol 2000;96:913-20.
18. Sulak PJ, Carl J, Gopalakrishnan I, Coffee A, Kuehl TJ. Outcomes of extended oral contraceptive regimens with a shortened hormone-free interval to manage breakthrough bleeding. Contraception 2004;70:281-7.
19. FDA: U.S. Food and Drug Administration [Internet]. Reference ID:3108156. Available at: http://www.fda.gov [cited 2012, Mar 21].
20. Collier CN, Harper JC, Cafardi JA, Cantrell WC, Wang W, Foster KW et al. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol 2008;58:56-9.
21. Sillem M, Schneidereit R, Heithecker R, Mueck AO. Use of an oral contraceptive containing drospirenone in an extended regimen. Eur J Contracept Reprod Health Care 2003;8:162-9.
22. Haider A, Shaw JC. Treatment of acne vulgaris. JAMA 2004;292:726-35.
23. Arowojolu AO, Gallo MF, Grimes DA, Garner SE. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2004;CD004425.
24. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA, Garner SE. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2009;CD004425.
25. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2012;7:CD004425.
26. Castelo-Branco C, Cancelo MJ. Comprehensive clinical management of hirsutism. Gynecol Endocrinol 2010;26:484-93.
27. Van der Spuy ZM, Le Roux PA. Cyproterone acetate for hirsutism. Cochrane Database Syst Rev 2003;CD001125.
28. Batukan C, Muderris II, Ozcelik B, Ozturk A. Comparison of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutism. Gynecol Endocrinol 2007;23:38-44.
29. Shannon M, Wang Y. Polycystic ovary syndrome:a common but often unrecognized condition. J Midwifery Womens Health 2012;57:221-30.
30. Royal College of Obstetricians and Gynaecologists [Internet]. Management of Premenstrual Syndrome. Green-top Guideline No. 48; London [Available from: http://www.rcog.org.uk/files/rcog-corp/uploaded-files/GT48ManagementPremensturalSyndrome.pdf [cited 2007, Dec 12].
31. Bargiota A, Diamanti-Kandarakis E. The effects of old, new and emerging medicines on metabolic aberrations in PCOS. Ther Adv Endocrinol Metab 2012;3:27-47.
32. Solomon CG. The epidemiology of polycystic ovary syndrome. Prevalence and associated disease risks. Endocrinol Metab Clin North Am 1999;28:247-63.
33. Nader S, Diamanti-Kandarakis E. Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. Hum Reprod 2007;22:317-22.
34. Soares GM, Vieira CS, de Paula Martins W, Dos Reis RM, de Sá MF, Ferriani RA. Metabolic and cardiovascular impact of oral contraceptives in polycystic ovary syndrome. Int J Clin Pract 2009;63:160-9.
35. Costello MF, Shrestha B, Eden J, Johnson NP, Sjoblom P. Metformin versus oral contraceptive pill in polycystic ovary syndrome:a Cochrane review. Hum Reprod 2007;22:1200-9.
36. Jing Z, Liang-Zhi X, Tai-Xiang W, Ying T, Yu-Jian J. The effects of Diane-35 and metformin in treatment of polycystic ovary syndrome: an updated systematic review. Gynecol Endocrinol 2008;24:590-600.
37. Halperin IJ, Kumar SS, Stroup DF, Laredo SE. The association between the combined oral contraceptive pill and insulin resistance, dysglycemia and dyslipidemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of observational studies. Hum Reprod 2011;26:191-201.
38. Vessey M, Metcalfe A, Wells C, McPherson K, Westhoff C, Yeates D. Ovarian neoplasms, functional ovarian cysts, and oral contraceptives. Br Med J 1987;294:1518-20.
39. Mishell DR Jr. Noncontraceptive health benefits of oral steroidal contraceptives. Am J Obstet Gynecol 1982;142:809-16.
40. Brun JL, Le Touzé O, Leng JJ. Medical and surgical treatment of functional ovarian cysts. J Gynecol Obstet Biol Reprod 2001;30:S41-52.
41. Grimes DA, Jones LB, Lopez LM, Schulz KF. Oral contraceptives for functional ovarian cysts. Cochrane Database Syst Rev 2011;CD006134.
42. Schrager S, Falleroni J, Edgoose J. Evaluation and treatment of endometriosis. Am Fam Physician 2013;87:107-13.
43. Vercellini P, Crosignani P, Somigliana E, Viganö P, Frattaruolo MP, Fedele L. 'Waiting for Godot': a commonsense approach to the medical treatment of endometriosis. Hum Reprod 2011;26:3-13.
44. Morelli M, Sacchinelli A, Venturella R, Mocciaro R, Zullo F. Postoperative administration of dienogest plus estradiol valerate versus levonorgestrel-releasing intrauterine device for prevention of pain relapse and disease recurrence in endometriosis patients. J Obstet Gynaecol Res 2013 [Epub ahead of print].
45. Garry R. The effectiveness of laparoscopic excision of endometriosis. Curr Opin Obstet Gynecol 2004;16:299-303.
46. Steinauer J, Autry AM. Extended cycle combined hormonal contraception. Obstet Gynecol Clin North Am 2007;34:43-55.
47. Davis L, Kennedy SS, Moore J, Prentice A. Modern combined oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev 2007;CD001019.
48. Harada T, Momoeda M, Taketani Y, Hoshiai H, Terakawa N. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. Fertil Steril 2008;90:1583-8.
49. Mabrouk M, Frascà C Geraci E Montanari G Ferrini G Raimondo D, et al. Combined oral contraceptive therapy in women with posterior deep infiltrating endometriosis. J Minim Invasive Gynecol 2011;18:470-4.
50. Brown J, Kives S, Akhtar M. Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database Syst Rev 2012;3:CD002122.
51. Johnson SR. Premenstrual syndrome, premenstrual dysphoric disorder, and beyond:a clinical primer for practitioners. Obstet Gynecol 2004;104:845-59.
52. Arlington VA. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Revision (DSM-IV-TR);2000.
53. Edelman AB, Gallo M-F, Jensen JT, Nichols MD, Schulz KF, Grimes DA. Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rev 2005;CD004695.
54. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 2005;72:414-21.
55. Coffee AL, Kuehl TJ, Willis S, Sulak PJ. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Am J Obstet Gynecol 2006;195:1311-9.
56. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2009;CD006586.
57. Maguire K, Westhoff C. The state of hormonal contraception today: established and emerging noncontraceptive health benefits. Am J Obstet Gynecol 2011;205:S4-8.
58. Chiaffarino F, Parazzini F, La Vecchia C, Marsico S, Surace M, Ricci E. Use of oral contraceptives and uterine fibroids: results from a case-control study. Br J Obstet Gynaecol 1999;106:857-60.
59. Friedman AJ, Thomas PP. Does low-dose combination oral contraceptive use affect uterine size or menstrual flow in premenopausal women with leiomyomas? Obstet Gynecol 1995;85:631-5.
60. Marshall LM, Spiegelman D, Goldman MB, Manson JE, Colditz GA, Barbieri RL et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril 1998;70:432-9.
61. Wise LA, Palmer JR, Harlow BL, Spiegelman D, Stewart EA, Adams-Campbell LL, et al. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women:a prospective study. Am J Epidemiol 2004;159:113-23.
62. Rubin GL, Ory HW, Layde PM. Oral contraceptives and pelvic inflammatory disease. Am J Obstet Gynecol 1982;144:630-5.
63. Burkman RT. Oral contraceptives: current status. Clin Obstet Gynecol 2001;44:62-72.
64. Henry-Suchet J. Hormonal contraception and pelvic inflammatory disease. Eur J Contracept Reprod Health Care 1997;2:263-7.
65. Huber JC, Bentz EK, Ott J, Tempfer CB. Non-contraceptive benefits of oral contraceptives. Expert Opin Pharmacofher 2008;9:2317-25.
66. Panser LA, Phipps WR. Type of oral contraceptive in relation to acute, initial episodes of pelvic inflammatory disease. Contraception 1991;43:91-9.
67. Cottingham J, Hunter D. Chlamydia trachomatis and oral contraceptive use:a quantitative review. Genitourin Med 1992;68:209-16.
68. Martins SL, Curtis KM, Glasier AR. Combined hormonal contraception and bone health:a systematic review. Contraception 2006;73:445-69.
69. Lopez LM, Grimes DA, Schulz KF, Curtis KM. Steroidal contraceptives: effect on bone fractures in women. Cochrane Database Syst Rev 2011;CD006033.
70. Nappi C, Bifulco G, Tommaselli GA, Gargano V, Di Carlo C. Hormonal contraception and bone metabolism:a systematic review. Contraception 2012;86:606-21.
71. Rohan TE, Miller AB. A cohort study of oral contraceptive use and risk of benign breast disease. Int J Cancer 1999;82:191-6.
72. Burkman RT, Collins JA, Shulman LP, Williams JK. Current perspectives on oral contraceptive use. Am J Obstet Gynecol 2001;185:S4-12.
73. McGonigle KF, Huggins GR. Oral contraceptives and breast disease. Fertil Steril 1991;56:799-819.
74. Brinton LA, Vessey MP, Flavel R, Yeates D. Risk factors for benign breast disease. Am J Epidemiol 1981;113:203-14.
75. Schlesselman JJ. Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner's guide to meta-analysis. Hum Reprod 1997;12:1851-63.
76. La Vecchia C, Altieri A, Franceschi S, Tavani A. Oral contraceptives and cancer: an update. Drug Saf 2001;24:741-54.
77. Weiderpass E, Adami HO, Baron JA, Magnusson C, Lindgren A, Persson I. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control 1999;10:277-84.
78. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. Combination oral contraceptive use and the risk of endometrial cancer. JAMA 1987;257:796-800.
79. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, International Agency for Research on Cancer, World Health Organization Hormonal Contraception and Post-Menopausal Hormonal Therapy. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 72, IARC. Distributed by IARC Press and the World Health Organization Distribution and Sales: Lyon, France, Geneva; 1999.
80. Ricciardi E, Maniglio P, Frega A, Marci R, Caserta D, Moscarini M. Fertility-sparing treatment of endometrial cancer precursors among young women:a reproductive point of view. Eur Rev Med Pharmacol Sci 2012;16:1934-7.
81. Mueck AO, Seeger H, Rabe T. Hormonal contraception and risk of endometrial cancer:a systematic review. Endocr Relat Cancer 2010;17:R263-271.
82. Fraser IS. Non-contraceptive health benefits of intrauterine hormonal systems. Contraception 2010;82:396-403.
83. Huber JC, Bentz EK, Ott J, Tempfer CB. Non-contraceptive benefits of oral contraceptives. Expert Opin Pharmacother 2008;9:2317-25.
84. Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. BMJ 2007;335:651.
85. Tworoger SS, Fairfield KM, Colditz GA, Rosner BA, Hankinson SE. Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Am J Epidemiol 2007;166:894-901.
86. th edition. Phildelphia: Lippincott Williams & Wilkins; 2010.
87. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis bf data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008;371:303-14.
88. Royar J, Becher H, Chang-Claude J. Low-dose oral contraceptives: protective effect on ovarian cancer risk. Int J Cancer 2001;95:370-4.
89. Antoniou AC, Rookus M, Andrieu N, Brohet R, Chang-Claude J, Peock S et al. Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev 2009;18:601-10.
90. Grenader T, Peretz T, Lifchitz M, Shavit L. BRCA1 and BRCA2 germ-line mutations and oral contraceptives: to use or not to use. Breast 2005;14:264-8.
91. Brohet RM, Goldgar DE, Easton DF, Antoniou AC, Andrieu N, Chang-Claude J et al. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study:a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol 2007;25:3831-6.
92. Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B, Radice P et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers:a meta-analysis. Eur J Cancer 2010;46:2275-84.
93. Bosetti C, Bravi F, Negri E, La Vecchia C. Oral contraceptives and colorectal cancer risk:a systematic review and meta-analysis. Hum Reprod Update 2009;15:489-98.
94. Long MD, Martin CF, Galanko JA, Sandler RS. Hormone replacement therapy, oral contraceptive use, and distal large bowel cancer: a population-based case-control study. Am J Gastroenterol 2010;105:1843-50.
95. Doran MF, Crowson CS, O'Fallon WM, Gabriel SE. The effect of oral contraceptives and estrogen replacement therapy on the risk of rheumatoid arthritis:a population based study. J Rheumatol 2004;31:207-13.
96. Camacho EM, Lunt M, Farragher TM, Verstappen SM, Bunn DK, Symmons DP. The relationship between oral contraceptive use and functional outcome in women with recent-onset inflammatory polyarthritis: results from the Norfolk Arthritis Register (NOAR). Arthritis Rheum 2011;63:2183-91.
97. Holmqvist ST, Hammar M, Lindblom AM, Brynhirdsen J. Age at onset of Multiple sclerosis is correlated to use of combined oral hormonal contraceptives and child birth before diagnosis. Fert Steril 2010;94:2835-7.
98. Centers for Disease Control and Prevention (CDC). U S. medical eligibility criteria for contraceptive use, 2010. MMWR Recomm Rep 2010;59:1-86.
99. Kailas NA, Sifakis S, Koumantakis E. Contraception during perimenopause. Eur J Contracept Reprod Health Care 2005;10:19-25.
100. Kaplan B, Nahum R, Yairi Y, Hirsch M, Pardo J, Yogev Y et al. Use of various contraceptive methods and time of conception in a community-based population. Eur J Obstet Gynecol Reprod Biol 2005;123:72-6.